Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioventus Inc.
Bioventus exercised a “call option” to acquire CartiHeal for about $315m, plus up to $135m in milestones. The US FDA recently approved CartiHeal’s Agili-C implant to treat knee joint surface lesions.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
- Implantable Devices
- Large Molecule
- Other Names / Subsidiaries
- Bioventus Inc.
- Bioventus Coöperatief U.A.
- BioStructures LLC
- Bioness, Inc.
- CartiHeal Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.